Australia’s trusted independent immunisation experts

Publications

Litt J, Booy R, Bourke D, Dwyer DE, Leeb A, McCloud P, Stein AN, Woodward M, Cunningham AL. Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2020.1754702. [Full text]

Sharma K, Perrett K, Wood N. Case Series: Yellow fever vaccination in egg-allergic children. Pediatric Infectious Disease Journal. 2020;39:e76-e78. doi: 10.1097/INF.0000000000002625. [Full text]

Totterdell J, Phillips A, Glover C, Chidwick K, Marsh J, Snelling T, Macartney K. Safety of live attenuated herpes zoster vaccine in adults 70 to 79 years: a self-controlled case series analysis using primary care data from the MedicineInsight program. Vaccine. 2020;38:3968-3979 . [Full text]

Pillsbury AJ, Fathima P, Quinn HE, Cashman P, Blyth CC, Leeb A, Macartney K . Comparative post-market safety profile of adjuvanted and high-dose influenza vaccines in the elderly. JAMA Open. 2020;3(5):e204079 . [Full text]

Deng L, Mab A, Wood N, Ardern-Holmes S. Vaccination management in an asymptomatic child with a novel SCN1A variant and family history of status epilepticus following vaccination: a case report on a potential new direction in personalised medicine. Seizure: European Journal of Epilepsy. 2020;78:49-52 . [Full text]

Leong NR, Wooda JG, Liu B, McIntyre PB, Newall AT . High healthcare resource utilisation due to pertussis in Australian adults aged 65 years and over. Vaccine. 2020;38:3553–3559 . [Full text]

Frank O, Bernardo C, Gonzalez-Chica DA, Macartney K, Menzies R, Stocks N . Pneumococcal vaccination uptake among patients aged 65 years or over in Australian general practice. Human Vaccines & Immunotherapeutics. 2020;16:965-971 . [Full text]

Netfa F, Tashani M, Booy R, King C, Rashid H, Skinner SR. Knowledge, Attitudes and perceptions of immigrant parents towards human papillomavirus (HPV) vaccination: a systematic review . Tropical Medicine and Infectious Disease. 2020;5:58 . [Full text]

Kaufman J, Attwell K, Tuckerman J, O'Sullivana J, Omar SB, Leask J, Regan A, Marshal H, Leea KJ, Snelling T, Perrett K, Wiley K, Giles ML, Danchin M. Feasibility and acceptability of the multi-component P3-MumBubVax antenatal intervention to promote maternal and childhood vaccination: a pilot study. Vaccine. 2020;38:4024-4031 . [Full text]

Wnukowski-Mtonga P, Jayasinghe S, Chiu C, Macartney K, Brotherton J, Donovan B, Hall M, Smith D, Peterson K, Campbell-Lloyd S, Selvey C, Gilles M, Kaldor J, Marshall H. Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia by the Australian Technical Advisory Group on Immunisation (ATAGI) . Communicable Diseases Intelligence. 15 April 2020. 2020;44 . [Full text]